Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F Pollock

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Advances in Therapy|March 16, 2019
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USAPierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Journal of Medical Economics|February 2, 2022
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitusRichard F Pollock, Kirsi Norrbacka, Kristina S Boye, et al.
International Journal of Clinical Pharmacy|April 3, 2023
A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltoseNicholas A Kennedy, Maureen M Achebe, Patrick Biggar, et al.
Advances in Therapy|March 22, 2025
Point of Care Nucleic Acid Testing for Influenza-Like Illness: A Cost-Consequence Analysis for High-Risk Patients in Primary Care in GermanyJohannes Pöhlmann, Anika Joecker, Tanja Wittki, et al.
Journal of Medical Economics|March 10, 2023
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UKKristin Grabe-Heyne, Christof Henne, Isaac Odeyemi, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 7, 2019
Cost-Effectiveness Of The SQ<sup>®</sup> Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer PerspectiveChristian Vogelberg, Eckard Hamelmann, Ulrich Wahn, et al.
Journal of Medical Economics|April 1, 2025
A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel diseaseStefan C Lindgren, Hans Strid, Henrik Hjortswang, et al.
Current Diabetes Reviews|December 15, 2010
Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetesRichard F Pollock, Katrina M Erny-Albrecht, Anupama Kalsekar, et al.
Frontiers in Oncology|June 19, 2023
Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needsKristin Grabe-Heyne, Christof Henne, Paramananthan Mariappan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes MellitusWilliam J Valentine, Richard F Pollock, Rhodri Saunders, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Advances in Therapy|March 16, 2019
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USAPierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Journal of Medical Economics|February 2, 2022
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitusRichard F Pollock, Kirsi Norrbacka, Kristina S Boye, et al.
International Journal of Clinical Pharmacy|April 3, 2023
A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltoseNicholas A Kennedy, Maureen M Achebe, Patrick Biggar, et al.
Advances in Therapy|March 22, 2025
Point of Care Nucleic Acid Testing for Influenza-Like Illness: A Cost-Consequence Analysis for High-Risk Patients in Primary Care in GermanyJohannes Pöhlmann, Anika Joecker, Tanja Wittki, et al.
Journal of Medical Economics|March 10, 2023
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UKKristin Grabe-Heyne, Christof Henne, Isaac Odeyemi, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 7, 2019
Cost-Effectiveness Of The SQ<sup>®</sup> Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer PerspectiveChristian Vogelberg, Eckard Hamelmann, Ulrich Wahn, et al.
Journal of Medical Economics|April 1, 2025
A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel diseaseStefan C Lindgren, Hans Strid, Henrik Hjortswang, et al.
Current Diabetes Reviews|December 15, 2010
Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetesRichard F Pollock, Katrina M Erny-Albrecht, Anupama Kalsekar, et al.
Frontiers in Oncology|June 19, 2023
Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needsKristin Grabe-Heyne, Christof Henne, Paramananthan Mariappan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes MellitusWilliam J Valentine, Richard F Pollock, Rhodri Saunders, et al.
Pageof 9